Australia markets close in 1 hour 56 minutes

Greenwich LifeSciences, Inc. (GLSI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
13.08-0.42 (-3.11%)
At close: 04:00PM EDT
13.08 0.00 (0.00%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.50
Open13.31
Bid0.00 x 0
Ask0.00 x 0
Day's range12.65 - 13.70
52-week range7.58 - 21.44
Volume30,711
Avg. volume43,185
Market cap173.88M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.69
Earnings date21 Aug 2024 - 25 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est36.00
  • Insider Monkey

    Insiders are Piling into These 10 Healthcare Stocks in 2024

    In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 Healthcare Stocks in 2024. Healthcare investors were nervous when 2024 started, since election years usually don’t bode well for healthcare stocks. But […]

  • GlobeNewswire

    Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

    STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 mont

  • GlobeNewswire

    Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

    STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa